Dr. Carsten Thiel was recently appointed to the office of President of EUSA Pharma in Europe. Dr. Darrel P Cohen was also appointed as Head of EUSA’s Clinical Development Department.
EUSA is a company that focuses on creating pharmaceuticals that treat rare diseases. Both Dr. Cohen and Dr. Thiel have extensive educations and experience to fill these positions and strengthen EUSA’s structure globally in clinical development.
Carsten Thiel attended the University of Marburg and has a Masters in Biochemistry as well as a PhD in Molecular Biology from Max Planck Institute in Germany. Dr. Thiel started his career at Hoffman La Roche. He held several positions at Amgen.
During his time at Amgen, Dr. Thiel was responsible for the development of several products that treated bone disorders, nephrology, and oncology. Carsten Thiel followed this up with a few years working for Alexion Pharmaceuticals Inc. and prior to his position at EUSA Europe Dr. Thiel held the position of CEO at Abeona Therapeutics focusing on US gene-based therapies.
Darrel P. Cohen attended the Boston University School of Medicine where he obtained an MD and a PhD in Microbiology. He has held the position of Director for Clinical research for Sanofi- Aventis. Dr. Cohen previously led the Clinical Development Center of Pfizer’s global oncology as Vice president and was responsible for helping in the development of several oncology products that were quite successful. In his long career, Dr. Darrel P. Cohen has held the positions of Associate in Medicine and Hematology/ Oncology fellow at the Duke University Medical Center. Dr. Darrel P. Cohen brings 20 years of experience as a hematologist/oncologist in clinical development to EUSA. Go To This Page to learn more.
Learn more about Thiel on https://uk.linkedin.com/in/carsten-thiel-8970b45